Advertisement
UK markets closed
  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     
  • HANG SENG

    18,868.71
    -326.89 (-1.70%)
     
  • CRUDE OIL

    76.91
    +0.04 (+0.05%)
     
  • GOLD FUTURES

    2,333.10
    -4.10 (-0.18%)
     
  • DOW

    39,065.26
    -605.78 (-1.53%)
     
  • Bitcoin GBP

    53,259.46
    -1,184.79 (-2.18%)
     
  • CMC Crypto 200

    1,468.56
    -34.10 (-2.27%)
     
  • NASDAQ Composite

    16,736.03
    -65.51 (-0.39%)
     
  • UK FTSE All Share

    4,543.84
    -16.71 (-0.37%)
     

Inspire Medical Systems, Inc. to Report First Quarter 2024 Financial Results on May 7, 2024

Inspire Medical Systems
Inspire Medical Systems

MINNEAPOLIS, April 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 7. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q1 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Inspire's Q1 2024 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

ADVERTISEMENT

Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443